Tropical medicine & international health : TM & IH · 2025
Leprosy in blood donors.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Oliveira Jorge Erika Vanessa, Gobbo Angélica Rita, Costa Izabelle Laissa Viana, Bouth Raquel Carvalho, da Silva Sâmela Miranda, Cunha Messias Ana Caroline, Barreto Josafá Gonçalves, da Costa Patrícia Fagundes, do Carmo Pinto Pablo Diego, da Silva Moises Batista, Spencer John Stewart, Palmeira Maurício Koury, Salgado Claudio Guedes
Аннотация
OBJECTIVES: We investigated the prevalence of anti-phenolic glycolipid-I (PGL-I) IgM antibodies among temporarily unfit blood donors at the Pará State Blood Bank (HEMOPA), located in the Amazon region of northern Brazil. Using an arbitrary high cutoff for optical density (OD ≥0.750) in ELISA, a subset of donors was invited for clinical evaluation for leprosy.
METHODS: Temporarily unfit individuals were invited to participate, and blood samples were collected for anti-PGL-I IgM titration by ELISA. Donors with high OD values were referred for clinical examination, slit skin smear (SSS) bacilloscopy, and quantitative PCR (qPCR) targeting M. leprae-specific repetitive element (RLEP) sequences from dermal scrapes of the earlobes and peripheral blood.
RESULTS: From an annual average of 2762 temporarily unfit donors (2019-2023), 500 (16.6%) were tested for anti-PGL-I IgM. Of these, 20/500 (4.0%) had high antibody titres, and 8/20 (40.0%) attended clinical evaluation, resulting in 5/8 (62.5%) newly diagnosed cases of leprosy. Among these, Mycobacterium leprae detection yielded positivity rates of 2/8 (25.0%) by SSS bacilloscopy, 3/7 (42.9%) by qPCR of dermal scrapes, and 2/8 (25.0%) by qPCR of peripheral blood.
CONCLUSIONS: Using an anti-PGL-I IgM cutoff of OD ≥0.750, we identified a significant proportion of undiagnosed leprosy cases among temporarily unfit blood donors. These findings support the need for targeted leprosy screening in this population. Regardless of qPCR results, individuals with clinical signs of leprosy require appropriate treatment and assessment of their eligibility for blood donation.
METHODS: Temporarily unfit individuals were invited to participate, and blood samples were collected for anti-PGL-I IgM titration by ELISA. Donors with high OD values were referred for clinical examination, slit skin smear (SSS) bacilloscopy, and quantitative PCR (qPCR) targeting M. leprae-specific repetitive element (RLEP) sequences from dermal scrapes of the earlobes and peripheral blood.
RESULTS: From an annual average of 2762 temporarily unfit donors (2019-2023), 500 (16.6%) were tested for anti-PGL-I IgM. Of these, 20/500 (4.0%) had high antibody titres, and 8/20 (40.0%) attended clinical evaluation, resulting in 5/8 (62.5%) newly diagnosed cases of leprosy. Among these, Mycobacterium leprae detection yielded positivity rates of 2/8 (25.0%) by SSS bacilloscopy, 3/7 (42.9%) by qPCR of dermal scrapes, and 2/8 (25.0%) by qPCR of peripheral blood.
CONCLUSIONS: Using an anti-PGL-I IgM cutoff of OD ≥0.750, we identified a significant proportion of undiagnosed leprosy cases among temporarily unfit blood donors. These findings support the need for targeted leprosy screening in this population. Regardless of qPCR results, individuals with clinical signs of leprosy require appropriate treatment and assessment of their eligibility for blood donation.